Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-altering. We initiated a phase 2 study in which patients with MIBC received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients achieving a clinical complete response (cCR) could proceed without cystectomy. The co-primary objectives were to assess the cCR rate and the positive predictive value of cCR for a composite outcome: 2-year metastasis-free survival in patients forgoing immediate cystectomy or
CITATION STYLE
Galsky, M. D., Daneshmand, S., Izadmehr, S., Gonzalez-Kozlova, E., Chan, K. G., Lewis, S., … Pal, S. K. (2023). Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nature Medicine, 29(11), 2825–2834. https://doi.org/10.1038/s41591-023-02568-1
Mendeley helps you to discover research relevant for your work.